AB569

Drug candidate for treating antibiotic resistant infections

Treatment for antibiotic resistant lung and urinary tract infections

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for AB569 in the treatment of Pseudomonas aeruginosa (P. aeruginosa)pulmonary infections in patients with...

AB569 Principal Scientist

Lead scientist for AB569 which targets Respiratory Pseudomonas Infections

[yjsgimgs image="images/arch_content_images/headshots/drHasset.png" class="" title="" link="" target="" effect="none"]

Dr. Hassett

Dr. Hassett is a Professor in the Department of Molecular Genetics, Biochemistry and Microbiology...

Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569

TORONTO, ONTARIO--(Marketwired - March 16, 2016) -Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today it has entered into an exclusive...

MetaMX™

Targeting Brain Tumor Initiating Cells

Brain Tumor Initiating Cell Targeting

MetaMx™ is composed of novel, synthetic peptides that target and attach to BTICs and invasive glioma cells, for the purpose of imaging, diagnosis and developing targeted therapies to improve patient outcomes...

MetaBlok and MetaMx Scientists

[yjsgimgs image="images/arch_content_images/headshots/sRobbins.png" class="" title="" link="" target="" effect="none"]

Stephen Robbins

Dr. Robbins is the Scientific Director of the CIHR's Institute of Cancer Research. He is currently an Associate Professor at the University of Calgary in the Departments of Oncology and Biochemistry & Molecular...

MetaBlok™

A potential treatment for sepsis and cancer metastasis

Blocking Sepsis

MetaBlok is a new drug candidate for the potential treatment of sepsis and cancer metastasis. 

MetaBlok was invented by Arch scientists Dr. Stephen Robbins, Dr. Donna Senger, Dr. Jennifer Rahn and their...

MetaBlok and MetaMx Scientists

Lead scientists for MetaBlok™ and MetaMx™

[yjsgimgs image="images/arch_content_images/headshots/sRobbins.png" class="" title="" link="" target="" effect="none"]

Stephen Robbins

Dr. Robbins is the Scientific Director of the CIHR's Institute of Cancer Research. He is currently an Associate Professor at the University of Calgary in the Departments of...

BORG

Peptide Solid Surface Interface

Peptide Solid Surface Interface

Arch has developed a group of novel synthetic peptides and peptide conjugates that employ a novel chemistry (non-toxic, and environmentally friendly process) to react with solid surfaces such as metals, and plastics...

BORG Peptide Solid Surface Interface Scientists

Lead scientists for BORG Peptides

[yjsgimgs image="images/arch_content_images/headshots/rIrvin.png" class="" title="" link="" target="" effect="none"]

Randall Irvin

Randall Irvin is Professor of Medical Microbiology and Immunology at the University of Alberta. He previously was a faculty...

Treatments for
Inflammation

Widespread application for the treatment of chronic diseases

As the population ages, the prevalence of chronic disease is on the rise and includes common conditions such as heart disease, diabetes, arthritis, inflammatory/infectious bowel disease and chronic...

Treatments for Inflammation Scientists

Lead scientists for Treatments for Inflammation

[yjsgimgs image="images/arch_content_images/headshots/dMuruve.png" class="" title="" link="" target="" effect="none"]

Daniel Muruve

Daniel Muruve is a Professor in the Department of Medicine at the University of Calgary. He graduated from...

NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis

Authors

Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, ...

    Bridging the gap between science and business

    Bringing new medical innovation to market.

    Arch Biopartners is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch works closely with the scientific community, universities and research institutions to advance and build the value of select preclinical technologies, harvest the most promising intellectual property, ...

    Investor Fundamentals

    Discover the Arch Biopartners story. Press releases, investor information, stock information, and our Reports and Filings are here.

    Management and Board of Directors

    Investor Relations and Investor Information